目的：检测CD39 在头颈鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）组织中的表达，分析其表达与患者临床病理特征的关系及其预后意义。方法：选用2012 年5 月至2013 年12 月在天津市肿瘤医院接受外科手术的85 例HNSCC患者的组织标本及病例资料，Oncomine 数据库获取的基因芯片，以及HNSCC细胞系SCC15、UM1 和Cal25。在线分析CD39 在HNSCC组织与正常颊黏膜组织转录水平的差异性，用Western blotting 和免疫组化法检测HNSCC组织中CD39 蛋白的表达。采用Spearman’s 检验分析HNSCC组织中CD39 的表达与患者临床病理特征的相关性，Kaplan-Meier 曲线法和Log rank 检验分析HNSCC组织CD39 表达与生存的关系，Cox风险比例回归模型评价CD39 表达与复发风险的关系。结果：CD39 在HNSCC组织的转录水平显著高于正常颊黏膜组织（P<0.01），其在HNSCC细胞Cal25、SCC-15 和UM1 中均有表达，UM1 细胞中CD39的表达呈地塞米松（dexamethasone, DXM）剂量依赖性。CD39 高表达患者53（62.4%）例，其高表达与术前化疗正相关（r=0.234，P<0.05），CD39 高表达患者的无复发生存期较低表达组显著缩短（P<0.05），CD39 高表达是HNSCC 复发的独立风险因素（HR=2.328，95%CI=1.091~4.967；P<0.05）。结论：CD39 在HNSCC中呈DXM诱导性表达和组成性表达，其在癌组织中过表达是HNSCC患者不良预后的独立预测因子，提示其在HNSCC进展过程中可能发挥重要作用。

Objective: To detect the expression of CD39 in head and neck squamous cell carcinoma (HNSCC) tisseus, and to analyze its correlation with patients’clinicopathological features and its prognostic significance. Methods: Tissue specimens and case data of 85 patients with HNSCC underwent surgery at Cancer Hospital of Tianjin from May 2012 to December 2013 were collected for this study. Gene chips were obtained from Oncomine database, and HNSCC cell lines SCC15, UM1, and Cal25 were selected for this study.Online analysis was performed to compare the differential expression of CD39 in buccal mucosa (BM) tissues and HNSCC tissues,Western blotting and Immunohistochemistry (IHC) were used to detect the protein expression of CD39 in HNSCC tissues. Spearman’s correlation analysis was used to study the correlation between the expressions of CD39 and clinicopathological features of HNSCC patients. Both Kaplan-Meier curve analysis and Log rank test were used to analyze the association between the expression of CD39 in HNSCC tissues and the survival of patients, and Cox risk proportional regression model was used to evaluate the relationship between CD39 expression and the risk of relapse. Results: The transcription level of CD39 was obviously up-regulated in HNSCC tissues than in BM tissues (P<0.01), and CD39 expression was detected in HNSCC cell lines SCC15, UM1 and Cal25. Dexamethasone (DXM)could enhance the expression of CD39 in UM1 cells in dose-dependent manner. CD39 was highly expressed in 53 (62.4%) HNSCC patients, which was positively correlated with preoperative chemotherapy (r=0.234, P<0.05). The recurrence-free survival (RFS) of patients with high CD39 expression was significantly shortened (P<0.05), and high CD39 expression was an independent relapse risk factor (HR=2.328, 95%CI=1.091-4.967; P<0.05) for patients with HNSCC. Conclusion: CD39 is DXM-inducively and constitutively expressed in HNSCC. And over-expression of CD39 is an independent predictor of poor prognosis in HNSCC patients, indicating its important role in the progression of HNSCC.

国家科技支撑计划资助项目（No.2015BAI12B00）；天津市卫生行业重点攻关项目（No. 15KG145）